SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects ...

Omeros also has identified MASP-3 as the protein that is critical to the activation of the complement system’s alternative pathway in humans, which is linked to a wide range of immune-related ...

The lectin pathway is the third pathway in the complement cascade, discovered after the classical and alternative pathways. It more closely resembles the classical pathway due to similar binding ...

The less time a tick has to feed, the less saliva it can pump in, and the fewer tricks it can use to tilt the odds. For ...

When drug development and the immune system collide we get CAR-T, checkpoint inhibitors, oncolytic vaccines, monoclonal antibodies and more. These fields have produced many therapies and garnered a ...

SEATTLE, July 31, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it believes it has identified the proteins that activate the alternative pathway of the complement system, ...

Figure 1: Mannose-binding lectin (blue strands) can bind to sites on the SARS-Cov-2 spike protein on the cell membrane. One of the most striking features of the SARS-CoV-2 pandemic is that across all ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug ...

Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

Among the most serious consequences of diabetes mellitus is the development of diabetic angiopathy, of which the clinical features are cardiovascular disease, retinopathy, nephropathy and neuropathy.